FOLLOWUS
Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin
- Chinese Journal of Integrative Medicine Vol. 18, Issue 1, Pages: 40-45(2012)
- Affiliations：
Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
DOI：10.1007/s11655-011-0874-0
CLC：Published：2012，
Published Online：8 December 2011，
Scan for full text
Tang, Xd., Liu, F., Li, L. et al. Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin., Chin. J. Integr. Med. 18, 40–45 (2012). https://doi.org/10.1007/s11655-011-0874-0
Xu-dong Tang, Feng Liu, Liu Li, et al. Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin. [J]. Chinese Journal of Integrative Medicine 18(1):40-45(2012)
Tang, Xd., Liu, F., Li, L. et al. Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin., Chin. J. Integr. Med. 18, 40–45 (2012). https://doi.org/10.1007/s11655-011-0874-0 DOI：
Xu-dong Tang, Feng Liu, Liu Li, et al. Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin. [J]. Chinese Journal of Integrative Medicine 18(1):40-45(2012) DOI： 10.1007/s11655-011-0874-0.
摘要
To explore the prognostic factors for very severe aplastic anemia (VSAA) patients treated mainly with Chinese Kidney (Shen)-invigorating drugs (CKID) combined with anti-lymphocyte globulin (ALG) or anti-thymocyte globulin (ATG). Twenty-seven VSAA patients were treated with CSID+ALG/ATG therapy in conjunction with cyclosporine A
androgen
hemopoietic growth factor
etc. The relationship of the effectiveness and some factors (age of patients
course of illness
blood and bone marrow figures
etc.) were analyzed. In the 25 evaluated VSAA patients who had been followed up for over 1 year
9 patients (36.0%) were basically cured
5 (20.0%) remitted
6 (24.0%) were markedly improved
and 5 (20.0%) were treated in vain
with the total effective rate of treatment being 80.0% (20/25). Better clinical therapeutic effects were shown in patients newly diagnosed with VSAA
of male sex (P=0.037)
>20 years old (P=0.045)
with an illness course ⩽ month (P=0.048)
with peripheral neutrophil count >0.1 × 109/L (P=0.023)
and with reticulocyte count >10 × 109/L (P=0.002). Platelet count (P=0.620) and bone marrow lymphocyte percentage (P=0.736) showed no correlation with the therapeutic effectiveness. Multi-factor analysis by the Kaplan-Meier procedure on the factors influencing survival showed that rather longer survival times occurred in patients > 20 years old
with peripheral neutrophil count ⩽ 0.1 × 109/L
reticulocyte count ⩽10 × 109/L
and platelet count > 10 × 109/L (all P=0.0001). Bone marrow lymphocyte percentage and the initiation time of ALG/ATG application (from onset of the illness) showed no significant influence on patients’ survival time (P=0.085 and P=0.935
respectively). CSKD+ALG/ATG therapy for treatment of VSAA could enhance the current clinical therapeutic effects and elevate patients’ survival rate. Conditions including male sex
age >20 years
illness course ⩽1 month
neutrophil count >0.1 × 109/L
and reticulocyte count >10 × 109/L are the likely effective indices for predicting favorable therapeutic effectiveness in newly diagnosed VSAA patients.
Abstract
To explore the prognostic factors for very severe aplastic anemia (VSAA) patients treated mainly with Chinese Kidney (Shen)-invigorating drugs (CKID) combined with anti-lymphocyte globulin (ALG) or anti-thymocyte globulin (ATG). Twenty-seven VSAA patients were treated with CSID+ALG/ATG therapy in conjunction with cyclosporine A
androgen
hemopoietic growth factor
etc. The relationship of the effectiveness and some factors (age of patients
course of illness
blood and bone marrow figures
etc.) were analyzed. In the 25 evaluated VSAA patients who had been followed up for over 1 year
9 patients (36.0%) were basically cured
5 (20.0%) remitted
6 (24.0%) were markedly improved
and 5 (20.0%) were treated in vain
with the total effective rate of treatment being 80.0% (20/25). Better clinical therapeutic effects were shown in patients newly diagnosed with VSAA
of male sex (P=0.037)
>20 years old (P=0.045)
with an illness course ⩽ month (P=0.048)
with peripheral neutrophil count >0.1 × 109/L (P=0.023)
and with reticulocyte count >10 × 109/L (P=0.002). Platelet count (P=0.620) and bone marrow lymphocyte percentage (P=0.736) showed no correlation with the therapeutic effectiveness. Multi-factor analysis by the Kaplan-Meier procedure on the factors influencing survival showed that rather longer survival times occurred in patients > 20 years old
with peripheral neutrophil count ⩽ 0.1 × 109/L
reticulocyte count ⩽10 × 109/L
and platelet count > 10 × 109/L (all P=0.0001). Bone marrow lymphocyte percentage and the initiation time of ALG/ATG application (from onset of the illness) showed no significant influence on patients’ survival time (P=0.085 and P=0.935
respectively). CSKD+ALG/ATG therapy for treatment of VSAA could enhance the current clinical therapeutic effects and elevate patients’ survival rate. Conditions including male sex
age >20 years
illness course ⩽1 month
neutrophil count >0.1 × 109/L
and reticulocyte count >10 × 109/L are the likely effective indices for predicting favorable therapeutic effectiveness in newly diagnosed VSAA patients.
关键词
acute aplastic anemiavery severe aplastic anemiaChinese Kidney-invigorating drugsanti-antilymphocyte globulinanti-thymocyte globulin
Keywords
acute aplastic anemiavery severe aplastic anemiaChinese Kidney-invigorating drugsanti-antilymphocyte globulinanti-thymocyte globulin
references
Tang XD, Zhang SS, Ma R, Xu YG, Yang XH, Xiao HY, et al. Preliminary study on predictors for selection of immunosuppressive therapy or androgens in treating aplastic anemia patients. Chin J Integr Tradit West Med (Chin) 2009;29:106–110.
Zhang ZN, Shen D, eds, Diagnosis and treatment standards for blood diseases. 3rd ed. Beijing: Science Press; 2007:19–23.
Summary of the Fourth National Conference on Aplastic Anemia by Chinese Society of Hematology, Chinese Medical Association. The efficacy and diagnostic criteria for aplastic anemia. Chin J Hematol (Chin) 1987;8:486.
Young NS. Pathophysiologic mechanisms in acquired aplastic anemia. Hematology Am Soc Hematol Educ Program 2006:72–77.
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236–1242.
Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130–1135.
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired apalstic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the Europen Group for Blood and Marrow Transplantation (EBMT). Haematogica 2007;92:11–18.
Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immuno-suppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol 2010;84:154–159.
Hattori M, Terasawa T, Tsushita K, Utsumi M, Kawano F, Saito H, et al. The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nation wide survey. Int J Hematol 2008;87:48–55.
Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastie anaemia. Br J Haematol 2009;144:206–216.
Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005;106:2102–2104.
Chen G, Kook H, Zeng W, Young NS, Maciejewski JP. Is there a direct effect of antithymocyte globulinon hematopoiesis? Hematol J 2004;5:255–261.
0
Views
116
Downloads
2
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
